Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | AGXT | P21549 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501299 | 0.80 | CA4 (0.34) | SLC6A2SLC6A4SLC6A3KCNH2KDM4E | |
| SCHEMBL6498977 | 0.72 | ELANE (0.49) | NPC1HPGDRAB9AKDM4E | |
| Cycloheptane SCHEMBL28102274 | 0.70 | CYP1A2 (0.86) | CYP1A2CYP2A6NPC1RAB9AKDM4E | |
| Pempidine SCHEMBL5934089 | 0.70 | TSHR (0.44) | CYP2A6SLC6A2SLC6A4SLC6A3HPGD | |
| SCHEMBL6490088 | 0.70 | PSMB1 (0.42) | SLC6A2SLC6A3NPC1HPGDRAB9A | |
| SCHEMBL16300520 | 0.70 | AGXT (0.41) | CYP1A2CYP2A6HRH3DRD3NPC1 | |
| SCHEMBL2356015 | 0.69 | TDP1 (0.39) | SLC6A2SLC6A4SLC6A3NPC1RAB9A | |
| SCHEMBL6721046 | 0.69 | HRH3 (0.46) | HRH3DRD3NPC1HPGDRAB9A | |
| SCHEMBL6491935 | 0.69 | CHRNB2 (0.41) | — | |
| SCHEMBL14048931 | 0.68 | RAB9A (0.45) | HRH3DRD3NPC1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579328-B2 | Preparation from a sterically hindered nitroxy compound and a diazonium salt of an aromatic amine in the presence of a transition metal catalyst | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | claimed |
| EP-1278733-A1 | PROCESS FOR THE PREPARATION OF STERICALLY HINDERED ARYLOXYAMINES | Ciba SC Holding AG (CH) | 2003-01-29 | — | — | EP | claimed |
| US-20020007585-A1 | Transition-metal-catalyzed process for the preparation of sterically hindered N-substituted aryloxyamines | CIBA SPECIALTY CHEMICALS CORP. | 2002-01-24 | — | — | US | claimed |
| WO-2001083455-A1 | PROCESS FOR THE PREPARATION OF STERICALLY HINDERED ARYLOXYAMINES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2001-11-08 | — | — | WO | claimed |
| US-6841668-B2 | Polyoxometalate catalysts for the preparation of sterically hindered N-substituted aryloxyamines | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2005-01-11 | — | — | US | disclosed |
| US-20030208071-A1 | Polyoxometalate catalysts for the preparation of sterically hindered N-substituted aryloxyamines | CIBA SPECIALTY CHEMICALS CORP. | 2003-11-06 | — | — | US | disclosed |
| US-6579328-B2 | Preparation from a sterically hindered nitroxy compound and a diazonium salt of an aromatic amine in the presence of a transition metal catalyst | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | disclosed |
| EP-1278733-A1 | PROCESS FOR THE PREPARATION OF STERICALLY HINDERED ARYLOXYAMINES | Ciba SC Holding AG (CH) | 2003-01-29 | — | — | EP | disclosed |
| US-20020007585-A1 | Transition-metal-catalyzed process for the preparation of sterically hindered N-substituted aryloxyamines | CIBA SPECIALTY CHEMICALS CORP. | 2002-01-24 | — | — | US | disclosed |
| WO-2001083455-A1 | PROCESS FOR THE PREPARATION OF STERICALLY HINDERED ARYLOXYAMINES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030208071-A1 | Polyoxometalate catalysts for the preparation of sterically hindered N-substituted aryloxyamines | KMO, PPOX, TAOK1 | CYP1A2 2516/4885CYP2A6 3584/4885HRH3 2692/4885 |
| US-20020007585-A1 | Transition-metal-catalyzed process for the preparation of sterically hindered N-substituted aryloxyamines | SOD1, NNMT, TYR | CYP1A2 240/4885CYP2A6 1586/4885HRH3 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.